Crispr Therapeutics Ag Stock Performance
| CRSP Stock | USD 55.24 0.49 0.88% |
The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Crispr Therapeutics will likely underperform. Crispr Therapeutics has an expected return of -0.66%. Please make sure to confirm Crispr Therapeutics maximum drawdown, as well as the relationship between the accumulation distribution and price action indicator , to decide if Crispr Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in June 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (0.88) | Five Day Return (1.50) | Year To Date Return (16.38) | Ten Year Return 292.05 | All Time Return 292.05 |
Last Split Factor 333333:100 | Last Split Date 2016-07-19 |
1 | STAT In a scientific first, researchers use CRISPR base editing to treat liver disease in fetal monkeys | 04/22/2024 |
2 | STAT Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief | 05/01/2024 |
3 | CRISPR Therapeutics AG Reports Q1 Loss, Misses Revenue Estimates | 05/08/2024 |
4 | Were Interested To See How CRISPR Therapeutics Uses Its Cash Hoard To Grow | 05/10/2024 |
5 | Excision BioTherapeutics Announces Data from the Phase 12 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B | 05/13/2024 |
6 | Is CRISPR Stock Going to 95 1 Wall Street Analyst Thinks So. | 05/15/2024 |
7 | BLUE vs. CRSP Why Are These Stocks Moving in Opposite Directions | 05/17/2024 |
8 | ERS Genomics and IRBM Sign CRISPRCas9 License Agreement | 05/20/2024 |
9 | Is CRISPR Therapeutics a Millionaire Maker | 05/22/2024 |
10 | CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments | 05/23/2024 |
| Begin Period Cash Flow | 224.1 M |
Crispr |
Crispr Therapeutics Relative Risk vs. Return Landscape
If you would invest 8,606 in Crispr Therapeutics AG on February 25, 2024 and sell it today you would lose (3,082) from holding Crispr Therapeutics AG or give up 35.81% of portfolio value over 90 days. Crispr Therapeutics AG is currently does not generate positive expected returns and assumes 2.4983% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Crispr, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Crispr Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crispr Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crispr Therapeutics AG, and traders can use it to determine the average amount a Crispr Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2641
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRSP |
Estimated Market Risk
| 2.5 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.66 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.26 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Crispr Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crispr Therapeutics by adding Crispr Therapeutics to a well-diversified portfolio.
Crispr Therapeutics Fundamentals Growth
Crispr Stock prices reflect investors' perceptions of the future prospects and financial health of Crispr Therapeutics, and Crispr Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crispr Stock performance.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0797 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (278.94) % | ||||
| Current Valuation | 2.86 B | ||||
| Shares Outstanding | 84.92 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 2.74 X | ||||
| Price To Sales | 13.87 X | ||||
| Revenue | 370 M | ||||
| Gross Profit | (570.7 M) | ||||
| EBITDA | (202.7 M) | ||||
| Net Income | (153.61 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 238.63 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 24.56 X | ||||
| Cash Flow From Operations | (260.38 M) | ||||
| Earnings Per Share | (2.70) X | ||||
| Market Capitalization | 4.73 B | ||||
| Total Asset | 2.23 B | ||||
| Retained Earnings | (999.7 M) | ||||
| Working Capital | 1.8 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
About Crispr Therapeutics Performance
To evaluate Crispr Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Crispr Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Crispr Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Crispr Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Crispr's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (42.64) | (40.51) | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.10) | (0.1) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.08) | (0.08) |
Things to note about Crispr Therapeutics performance evaluation
Checking the ongoing alerts about Crispr Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crispr Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Crispr Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 370 M. Net Loss for the year was (153.61 M) with loss before overhead, payroll, taxes, and interest of (570.7 M). | |
| Crispr Therapeutics AG currently holds about 2.07 B in cash with (260.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.48. | |
| Crispr Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments |
- Analyzing Crispr Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crispr Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Crispr Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crispr Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crispr Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crispr Therapeutics' stock. These opinions can provide insight into Crispr Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.70) | Revenue Per Share 3.396 | Quarterly Revenue Growth (0.99) | Return On Assets (0.08) | Return On Equity (0.11) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.